Welcome to our dedicated page for Regen Biopharma news (Ticker: RGBPP), a resource for investors and traders seeking the latest updates and insights on Regen Biopharma stock.
Regen BioPharma PFD A (RGBPP) is a preferred share class of Regen BioPharma, Inc., a publicly traded biotechnology company on the OTC Pink marketplace. Company news for RGBPP reflects developments at Regen BioPharma in immunology, immunotherapy, and its lead cell‑based therapeutic program, HemaXellerate.
News releases highlight Regen BioPharma’s efforts to advance HemaXellerate, a stem cell‑derived therapy designed to stimulate bone marrow regeneration and restore healthy blood cell production. The company reports FDA Investigational New Drug clearance for HemaXellerate and has discussed plans and preparations for a Phase I clinical trial in aplastic anemia, a rare and serious bone marrow disorder.
Investors following RGBPP news can also see updates on Regen BioPharma’s regulatory interactions, including submission of an Orphan Drug Application for HemaXellerate in aplastic anemia and the company’s process of addressing FDA comments on that application. Additional news items describe the exploration of chemotherapy‑induced bone marrow suppression as a second indication, positioning HemaXellerate as a potential multi‑lineage regenerative approach in oncology supportive care.
Beyond HemaXellerate, Regen BioPharma news covers its broader pre‑clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs for cancer and autoimmune disorders. The company frequently uses Emerging Growth Conference presentations to discuss scientific progress, clinical plans, and programs such as DuraCAR, offering investors and analysts a forum to ask questions in real time.
For holders and prospective investors in RGBPP, this news feed provides a centralized view of Regen BioPharma’s scientific updates, clinical trial planning, orphan drug strategy, and capital markets communications related to its immunology and immunotherapy focus.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.